Larry Borish headshot

Larry Borish

Unit: School of Medicine
Department: Department of Medicine, Allergy and Immunology
Office location and address
UVA Medical Park Northridge
2955 Ivy Rd
Charlottesville, Virginia 22903
Boston University, 1979, MD

Larry Borish did his undergraduate work at Harvard College where he received his B.A. (cum laude) in music in 1975. He received his M.D. from Boston University in 1979, after which he returned to Harvard for an internal medicine residency that was completed in 1982. Dr. Borish did his clinical training in allergy/immunology at the New England Medical Center followed by several years of post-doctoral fellowship training in research in the laboratories of Dr. Ross Rocklin and Dr. Lanny Rosenwasser. 

Dr. Borish was a faculty member at Tufts Medical School prior to his move to Colorado in 1989. From 1989 to 1999 he was an associate professor in medicine at the University of Colorado Health Sciences Center and a staff physician/principal investigator at the National Jewish Medical and Research Center. He is currently a Professor of Medicine at the University of Virginia and holds appointments in the Asthma and Allergic Diseases Center, the University of Virginia Cancer Center, and the Carter Immunology Center. He is on the editorial board for the Journal of Allergy and Clinical Immunology, and is an Associate Editor of the American Journal of Rhinology & Allergy. He has recently been elected to the board of directors of the American Board of Allergy and Immunology. His NIH-funded research interests include immune and molecular mechanisms of cytokine genes and cysteinyl leukotrienes in upper and lower airway allergic inflammation.

In particular, his laboratory has been investigating molecular mechanisms of aspirin-exacerbated respiratory disease, focusing on the role of cysteinyl leukotrienes and leukotriene receptors. More recently his laboratory has been involved in wide-ranging collaborative studies at the University of Virginia addressing mechanisms of rhinovirus-mediated asthma exacerbations. These studies focus on the role of innate immunity as well as expression of a high Th2 /low IL-10 cytokine signature by RV-targeting CD4+ and CD8+ T cells.

His clinical interests include chronic sinusitis, severe asthma, aspirin-exacerbated respiratory disease, primary immune deficiencies, and autoimmune mechanisms in chronic urticaria. He continues to play the oboe on rare occasions but is not prepared to give up his day job.

Protracted clinical and inflammatory response to rhinovirus challenge in human asthmatics
Source: U.S. NIH Institute of Allergy & Infectious Disease
March 01, 2022 – February 28, 2023
MD-INMD-Allergy Clinical response to rhinovirus in human asthmatics
Source: U.S. NIH Institute of Allergy & Infectious Disease
April 13, 2016 – September 30, 2022
Lung rhinovirus (RV) infection identifies pre-school children with type 2 inflammation at risk for the development of asthma
Source: U.S. NIH Institute of Allergy & Infectious Disease
March 01, 2020 – August 31, 2022
Undetectable IgE as a sentinel biomarker for humoral immunodeficiency
Source: Csl Behring L.L.C.
April 07, 2020 – July 30, 2022
Interleukin-5 Receptor Expression in COPD
Source: GlaxoSmithKline LLC
October 21, 2019 – April 20, 2022
Interleukin-5 Receptor (IL-5R¿) Expression by Neutrophils:A Therapeutic Target in Severe Asthma
Source: AstraZeneca
April 18, 2018 – May 31, 2020
UVA Allergy
Source: Food Allergy Research & Education, Inc.
January 01, 2017 – December 31, 2018
An Evaluation of Treatment with Omalizumab to Improve the Asthmatic Response
Source: U.S. NIH Institute of Allergy & Infectious Disease
August 03, 2012 – July 31, 2017
Interplay between LTE4/LTE4 receptors and IFN-y with mast cells and eosinophils i
Source: U.S. NIH Institute of Allergy & Infectious Disease
May 01, 2011 – July 31, 2016
MD-INMD-ALLERGY Clinical Immune Response to Rhinovirus Challenge in Human Asthmatics
Source: U.S. NIH Institute of Allergy & Infectious Disease
June 18, 2015 – July 31, 2016
MD-INMD-ALLERGY Long-Term Natural History of Patients with Severe or Difficult-to-Treat Asthma from the TENOR Observational Study
Source: Novartis Pharmaceuticals Corporation
July 23, 2014 – July 31, 2016
MD-INMD Allergic Disease in Neighbors of Concentrated Animal Feeding Operations
Source: Alpha Omega Alpha Honor Medical Society
February 05, 2014 – February 04, 2015
PATH 8280: Clinical Immunology and Immunopathology
Credits: 2
This course will review clinical conditions caused by aberrant performance of the immune system, including their clinical presentations and consequences. Students will appreciate the pathological and immune dysfunction responsible for each disease and important areas of contemporary immune research that address critical components of each disease's pathogenesis. Students will propose, delineate, and critique a focused research plan.
  • 2002: John McGovern Lectureship, American College of Allergy, Asthma, and Immunology
  • 2003: Pfizer Visiting Professor Award, St. Louis University, St., Louis, MO
  • 2004: Betty Wray Lectureship, American College of Allergy, Asthma, and Immunology
  • 2005-2018 Best Doctor in America® (Allergy/Immunology) by Best Doctors, Inc.
  • 2013-19: American Board of Allergy, Asthma, Immunology, Board of Directors